The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...

The FDA has approved a first-of-its-kind portable, noninvasive device that delivers alternating electrical fields for the ...

Optune Pax® with the chemotherapy combination of gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer.

The FDA has cleared a wearable device for adults with locally advanced pancreatic cancer that delivers low-intensity electric fields through adhesive patches placed on the skin. In the pivotal ...

The FDA has approved a first-of-its-kind wearable electrical device — Optune Pax (Novocure) — for patients with locally ...

The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

The main take-home message is that regulatory approval doesn't mean a device works. It means it's safe,” according to Katya ...

The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer. Optune Pax, developed by Novocure, is a ...

A first-of-its-kind device for pancreatic cancer treatment has been approved by the U.S. Food and Drug Administration.

First approved therapy for locally advanced disease in almost three decades ...

Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.